The transition of women’s health from a fragmented venture capital category into a centralised pillar of global healthcare acquisition strategies marks a definitive shift in the life sciences landscape. In early 2026, the sector has moved beyond the proof-of-concept phase that characterized the early 2020s, entering a period of aggressive consolidation where established healthcare conglomerates, private equity firms, and digital diagnostic leaders are acquiring specialized pl